Illumina (NASDAQ:ILMN) Given New $139.00 Price Target at Robert W. Baird

Illumina (NASDAQ:ILMN) had its price target lifted by Robert W. Baird from $124.00 to $139.00 in a research note released on Wednesday,Benzinga reports. They currently have a neutral rating on the life sciences company’s stock.

Several other brokerages have also weighed in on ILMN. Royal Bank of Canada lifted their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Wednesday, August 28th. TD Cowen lifted their price target on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Scotiabank cut their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research note on Thursday, August 15th. Finally, Barclays lifted their price target on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $162.18.

Illumina Stock Performance

NASDAQ ILMN opened at $151.09 on Wednesday. The stock has a 50-day simple moving average of $138.09 and a two-hundred day simple moving average of $123.56. The firm has a market capitalization of $24.07 billion, a P/E ratio of -15.17 and a beta of 1.13. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 0.86 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business posted $0.33 EPS. On average, equities analysts forecast that Illumina will post 4.11 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. raised its position in shares of Illumina by 426.0% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock worth $2,123,000 after purchasing an additional 12,521 shares during the last quarter. Jupiter Asset Management Ltd. acquired a new position in shares of Illumina during the 1st quarter worth approximately $4,527,000. US Bancorp DE raised its position in shares of Illumina by 33.9% during the 1st quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock worth $4,339,000 after purchasing an additional 8,001 shares during the last quarter. Cetera Advisors LLC acquired a new position in shares of Illumina during the 1st quarter worth approximately $610,000. Finally, Weybosset Research & Management LLC raised its position in shares of Illumina by 92.0% during the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after purchasing an additional 8,650 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.